Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4-Reference-Cited by-同舟云学术

Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4

Published:2018-01 Issue:1 Volume:68 Page:53-62
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Esmat Gamal,Elbaz Tamer,El Raziky Maissa,Gomaa Asmaa,Abouelkhair Mahmoud,Gamal El Deen Hadeel,Sabry Aliaa,Ashour Mohamed,Allam Naglaa,Abdel-Hamid Mohamed,Nada Ola,Helmy Sherine,Abdel-Maguid Hanaa,Colonno Richard,Brown Nathaniel,Ruby Eric,Vig Pamela,Waked Imam

Publisher

Elsevier BV

Subject

Hepatology

Reference46 articles.

1. The Polaris Observatory, Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study;Lancet Gastro Hepatol,2016

2. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013;Stanaway;Lancet,2016

3. Hepatitis C Genotype-4: What We Know and What We Don’t Yet Know;Kamal;Hepatology,2008

4. Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype-4;Khuroo;Aliment Pharmacol Ther,2004

5. Hepatitis C: the end of the beginning and possibly the beginning of the end;Alter;Ann Intern Med,2012

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Developments in small molecule antiviral drugs against hepatitis B and C viruses: FDA approved therapies and new drugs in clinical trials;Arabian Journal of Chemistry;2023-08

2. Occult Hepatitis (B) Infection in Hepatitis (C) Virus Infection Patients after the Treatment with Direct Acting Antiviral Drugs;Open Access Macedonian Journal of Medical Sciences;2022-06-23

3. Safety and efficacy of sofosbuvir‐based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta‐analysis;Journal of Clinical Pharmacy and Therapeutics;2022-06-08

4. Pharmacokinetics, Safety, and Tolerability of Ravidasvir, with and without Danoprevir/Ritonavir, in Healthy Subjects;Antimicrobial Agents and Chemotherapy;2021-09-17

5. Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial;The Lancet Gastroenterology & Hepatology;2021-06